Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.
Annamaria Gulla, MD, Dana-Farber Cancer Institute, is an LLS Career Development Program Fellow. With support from LLS, Dr. Gulla is working to improve outcomes for multiple myeloma patients through the power of immunotherapy. Immunotherapy – harnessing the immune system to fight cancer – has become a mainstay in cancer treatment. One promising approach centers on the evidence that cancer cells dying from specific treatment can be recognized by the patient’s own immune system, triggering an immune response against the disease. Dr. Gulla aims to characterize the molecular mechanisms behind this process – called immunogenic cell death – in multiple myeloma.
Today is International Childhood Cancer Day, a day that had little significance for me less than four short years ago. In October 2017, I heard the words, “Your child has cancer,” which I soon learned could only be eclipsed by, “there is nothing more we can do.”
To commemorate Black History Month, LLS is highlighting exceptional clinicians and healthcare professionals throughout the month of February. Dr. Rayne Rouce is a physician at Texas Children's Cancer Center where she is a member of the Leukemia/Lymphoma/Bone Marrow Transplant/Stem Cell Transplant Program. Dr. Rouce is board certified in pediatrics and pediatric hematology/oncology by the American Board of Pediatrics.
The Leukemia & Lymphoma Society (LLS), the global leader in the fight against blood cancer, and Burlington Stores, the national retailer delivering amazing deals to customers every time they shop, teamed up for the 19th consecutive year to raise critical funds to support LLS’s goal of creating a world without blood cancer, and to furthering their LLS Children’s Initiative, a $100 million multi-year endeavor to help children not only survive, but thrive after treatment.